Citicol500 mg/4 ml

Citicol is a naturally occurring nucleotide (cytidine diphosphate-choline, CDP-choline) precursor of phospholipids used mainly as a nootropic/neuroprotective adjunct. It is not an FDA-approved prescription drug in the United States, where it is sold as a dietary supplement, but it is a registered pharmaceutical product in Bangladesh and many other countries. Its uses can be classified by strength of evidence as follows:

Guideline-/label-supported adjunct uses (regional labeling)

• Adjunct treatment in acute ischemic stroke, generally started within 24 hours of symptom onset, to support recovery of consciousness and reduction of neurological/motor deficit — used alongside standard stroke management, not as a replacement for it.
• Adjunct treatment of cognitive impairment associated with cerebrovascular disease/stroke recovery — evidence across trials is moderate and mixed, so Citicol is used as supportive therapy rather than a primary treatment.
• Adjunct treatment for recovery after traumatic brain injury (TBI) or head trauma, including support of consciousness recovery and functional recovery — evidence is variable across studies and it is used as an adjunct to standard neurological care.

Adjunct / off-label or lower-evidence uses seen in some markets

• Cognitive dysfunction associated with Alzheimer's disease or other dementias — used as adjunct/supportive therapy in some regional labels; evidence for meaningful long-term benefit is limited.
• Co-therapy in Parkinson's disease, sometimes combined with levodopa-based regimens to support cognitive/functional status — see Interactions regarding its effect on levodopa.
• Amblyopia and certain ophthalmic/glaucoma-related uses reported in some literature — evidence is limited and this is not an established primary indication.

Citicol is not a cure for stroke, brain injury, or dementia; it is intended to be used in combination with, not instead of, standard medical and rehabilitative care, and the underlying condition should be diagnosed and managed by a physician.

Products containing Citicoline Sodium that are marketed in Bangladesh are commonly available as tablets (typically 500 mg citicoline base per tablet) and as an injectable solution (typically 500 mg/4 mL) for intramuscular or intravenous use. Exact strength, salt form, and excipients vary by manufacturer and brand — always check the product label/pack insert of the specific brand dispensed.

Citicol is the sodium salt of citicoline, a naturally occurring nucleotide (cytidine 5'-diphosphocholine, CDP-choline) that serves as an essential intermediate in the biosynthesis of phosphatidylcholine, a major structural phospholipid of neuronal and other cell membranes. Given orally or parenterally, Citicol is broken down into its constituent choline and cytidine moieties, which are absorbed and cross the blood-brain barrier before being recombined into citicoline within brain tissue. It is used mainly as a neuroprotective/nootropic adjunct to support recovery of brain function after ischemic or traumatic injury and in cognitive impairment associated with cerebrovascular disease, alongside standard medical management.

Citicol belongs to the nootropic/neuroprotective agents class (cholinergic precursor, psychostimulant/cognition-enhancing agent group). It is used therapeutically as an adjunct agent in cerebrovascular disease, traumatic brain injury recovery, and cognitive impairment.

Citicoline Sodium acts through several complementary mechanisms:

• Phospholipid membrane repair: as an intermediate in the Kennedy pathway, it provides choline and cytidine substrates needed for synthesis of phosphatidylcholine and other structural phospholipids, supporting repair of damaged neuronal and mitochondrial membranes.
• Neurotransmitter support: increases availability of choline for acetylcholine synthesis and has been shown to support dopaminergic neurotransmission, which underlies its adjunct use in Parkinson's disease and cognitive disorders.
• Neuroprotection during ischemia/hypoxia: stabilizes cell membranes, reduces free fatty acid accumulation and oxidative stress, and inhibits phospholipase A2 activation, limiting apoptotic neuronal cell death during and after ischemic injury.

Pharmacokinetics: after oral or parenteral administration, Citicoline Sodium is almost completely absorbed/bioavailable and is hydrolyzed into choline and cytidine, which are distributed widely, cross the blood-brain barrier, and are incorporated into phospholipid and nucleotide pools. Only a small fraction is excreted unchanged, mainly in urine and as respiratory carbon dioxide, with the remainder incorporated into structural components of the body.

Take oral Citicol tablets with a glass of water; they may be taken with or without food. Swallow tablets whole unless the product labeling states otherwise. Take doses at evenly spaced intervals as directed and do not double a dose to make up for one missed. Injectable Citicol is given only by a doctor or trained healthcare worker, by intramuscular injection or by slow intravenous injection/infusion — do not attempt to self-administer the injectable form.

The following interactions with Citicol are recognized as clinically relevant or important precautions:

• Levodopa (and levodopa-containing combinations, e.g., with carbidopa): Citicol may potentiate/enhance the effects of levodopa, which can be therapeutically useful in Parkinson's disease but may also increase the risk of levodopa-related adverse effects (such as dyskinesia); dose adjustment and monitoring by the physician may be needed when combined.
• Anticholinergic drugs: because Citicol supports cholinergic neurotransmission, there is a theoretical antagonistic interaction with anticholinergic medicines, which may reduce the effectiveness of one or both agents; use together with caution.
• Other centrally acting drugs (e.g., CNS stimulants, sedatives, other nootropic or psychoactive agents): theoretical additive or interactive CNS effects are possible; use in combination with caution and physician guidance.
• Meclofenoxate-containing products: concurrent use with meclofenoxate is generally not recommended per some regional labeling.

Citicol is generally well tolerated. Reported side effects include:

Patients should seek medical advice if side effects are severe or persistent.

Pregnancy: Robust controlled human safety data for Citicol in pregnancy are limited. Citicol should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; a physician should be consulted before use.

Lactation: It is not well established whether Citicol or its metabolites pass into human breast milk in clinically significant amounts. As a precaution, use during breastfeeding should occur only if a physician determines the expected benefit outweighs any potential risk to the nursing infant.

• Parasympathetic (vagotonic) hypertonia: avoid use in patients with severe parasympathetic hypertonia — see Contraindications.
• Blood pressure effects: because Citicol can occasionally affect blood pressure, use with caution in patients with unstable blood pressure or those on antihypertensive therapy.
• Driving and operating machinery: Citicol may occasionally cause dizziness or drowsiness in some patients; caution is advised until individual response is known.
• Hepatic or renal impairment: limited specific data are available; use with caution and physician-guided monitoring in patients with significant hepatic or renal disease.
• Concomitant use with levodopa or anticholinergic/centrally acting drugs: see Interactions.

Reported clinical experience with overdose of Citicol is limited, and it has a wide margin of safety at recommended doses; however, excessive doses could theoretically increase the frequency or severity of known side effects (such as gastrointestinal upset, changes in blood pressure, or dizziness).

If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center right away. Treatment should be supportive and symptomatic and carried out under medical supervision; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: commonly used in elderly patients for stroke and cognitive indications; no major specific dose adjustment is established, but use with routine clinical monitoring, particularly for blood pressure effects.
• Children: safety and efficacy of Citicol in children have not been well established; use in pediatric patients should only be under specialist medical supervision. See Pediatric Uses.
• Hepatic impairment: limited specific data; use with caution and physician guidance.
• Renal impairment: limited specific data; use with caution and physician guidance.
• Pregnancy and lactation: see Pregnancy and Lactation.

Duration of treatment with Citicol depends on the indication and clinical response. In acute ischemic stroke, treatment is often started early after the event and continued for several weeks as directed by the treating physician. For post-stroke cognitive impairment and traumatic brain injury recovery, courses of several weeks to a few months are commonly used in regional practice, with periodic reassessment of benefit by the physician. Citicol should not be continued indefinitely without medical review, and the prescribing physician should determine when to continue, adjust, or stop therapy.

Nootropic/neuroprotective agents; Cholinergic precursors (cytidine diphosphate-choline analogues); Cerebral metabolic enhancers

Citicoline Sodium supplies choline and cytidine, the two building blocks needed by the Kennedy pathway to synthesize phosphatidylcholine and other structural phospholipids of neuronal cell and mitochondrial membranes. By supporting repair of damaged membranes, increasing acetylcholine and dopamine neurotransmitter availability, stabilizing cell membranes during hypoxic/ischemic stress, and reducing free-radical-mediated and apoptotic neuronal injury, Citicoline Sodium helps support recovery of neurological and cognitive function after ischemic stroke, traumatic brain injury, and in chronic cerebrovascular cognitive impairment.

Safety and efficacy of Citicol in children have not been well established through large controlled pediatric trials, and it is not a standard first-line therapy in children. Where used in pediatric neurology practice (for example, in some cases of pediatric traumatic brain injury or developmental/cognitive support), this should occur only under the supervision of a specialist physician, with dosing individualized to the child's age, weight, and clinical condition rather than following adult dosing directly.